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Abstract. Marginal zone lymphomas have been associated with several infectious agents covering 
both viral and bacterial pathogens and in some cases a clear aetiological role has been 
established. Pathogenetic mechanisms are currently not completely understood. However, the 
role of chronic stimulation of the host immune response with persistent lymphocyte activation 
represents the most convincing explanation for lymphoproliferation. Gastric MALT lymphoma 
is strictly associated with Helicobacter pylori infection and various eradicating protocols, 
developed due to increasing antibiotic resistance, represent the first line therapy for gastric 
MALT. The response rate to eradication is good with 80% of response at 1 year; this finding is 
also noteworthy because it recapitulates cancer cured only by the antibacterial approach and it 
satisfies the Koch postulates of causation, establishing a causative relationship between Hp and 
gastric MALT lymphoma. Patients with chronic HCV infection have 5 times higher risk to 
develop MZL, in particular, an association with splenic and nodal MZL has been shown in 
several studies. Moreover, there is evidence of lymphoma regression after antiviral therapy with 
interferon+ribavirin, thus raising hope that newly available drugs, extremely efficient against 
HCV replication, could improve outcome also in HCV-driven lymphomas. Another case-study 
are represented by those rare cases of MZL localized to orbital fat and eye conjunctivas that 
have been associated with Chlamydophila psittaci infection carried by birds. Efficacy of 
antibacterial therapy against C. psittaci are conflicting and generally poorer than gastric MALT. 
Finally, some case reports will cover the relationship between primary cutaneous B-cell 
Lymphomas and Borrelia Burgdorferi. 
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Introduction. Marginal zone lymphoma (MZL) is 
a heterogeneous group of low-grade, B-cell, non-
Hodgkin lymphomas comprising three distinct 
diseases: extranodal MZL (EMZL) of mucosa-
associated lymphoid tissue (MALT), splenic MZL 
(SMZL), and nodal MZL (NMZL).1 In recent European 
studies, MZL has been reported in 12% of new 
lymphoma diagnoses,2 while a lower incidence of 3% 
was reported in the United States from Surveillance, 
Epidemiology, and End Results (SEER) registries.3 
Various contributing factors have been defined in terms 
of pathogenesis, including autoimmune diseases 
(mainly Sjögren syndrome and chronic autoimmune 
thyroiditis)4 while also several infectious agents are 
known or simply suspected to cause MZL. Mainly 
three mechanisms linking infections to MZL have been 
hypothesized:  
1) lymphocyte-transforming viruses can infect 
lymphocytes inducing dysregulation of normal cell 
functions and promotion of cell division (Epstein–Barr 
virus, Human Herpesvirus 8, Human T-lymphotropic 
virus type I);  
2) induction of immune suppression through 
progressive depletion of CD4+ T-lymphocytes, as in 
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AIDS (Human immunodeficiency virus) or in patients 
submitted to therapeutic immunosuppression;  
3) stimulation of chronic immune response and 
persistent lymphocyte activation (Helicobacter pylori, 
Hepatitis C virus, Chlamydophila psittaci, Borrelia 
burgdorferi, Campylobacter jejuni).5 
Specific organisms have been implicated in the 
aetiology of MZL involving particular anatomic sites:6 
Helicobacter pylori for the stomach, Chlamydophila 
psittaci for the ocular adnexa, Borrelia burgdorferi for 
the cutis,Campylobacter jejune for the small intestine, 
Mycobacterium spp. For the bronchus, Hepatitis C 
virus (HCV) for splenic and nodal MZL. However, a 
robust association is present only in gastric MALT 
lymphoma with Helicobacter pylori (Hp), where 90% 
of cases are Hp+.7 Moreover, Hp eradication therapy is 
effective in gastric MALT Hp+ lymphoma with a 
remission rate around 80%8,9 and also long-term results 
are excellent.10 The studies on Hp and gastric MALT 
lymphoma have profoundly influenced our 
understanding of the pathogenesis of lymphomas and 
modified our management, because, for the first time in 
the history of medical oncology, cancer has been cured 
by antibiotic therapy. 
This review focuses on the role of pathogens and 
development of MZL, with implication on the 
therapeutic option to target the implied infectious 
agents. 
 
Gastric MALT Lymphoma. 
The clinical presentation of gastric involvement by 
MALT lymphoma is variable and not specific with 
abdominal pain being the most common symptom, 
followed by dyspepsia, vomiting, nausea and anorexia; 
weight loss is common; gastric bleeding occurs as 
presenting symptom in 20%–30% of patients, while 
gastric occlusion and perforation are less common.11 
Diagnosis is made after histopathological evaluation of 
gastric biopsy, generally after 
esophagogastroduodenoscopy, and rely on the 
morphologic demonstration of the “hallmark” of 
MALT lymphoma: the lymphoepithelial lesion that 
results from invasion by atypical lymphocytes of 
epithelial mucosa and invasion of the glandular 
epithelium, as well as reactive lymphoid follicles.12 
Paradoxically, the stomach is the commonest site of 
MALT lymphoma, despite MALT tissue is not 
normally present in gastric mucosa. However, 
differentiation from other indolent lymphomas 
(Follicular lymphoma, Mantle-cell lymphoma) and 
aggressive lymphoma (Diffuse large B-cell lymphoma 
and Peripheral T-cell lymphoma) is not always 
straightforward, and a minimum 
immunohistochemistry panel including CD20, CD10, 
CD5 and cyclin D1 is recommended.13 Since the 
diagnosis should be made according to the WHO 
criteria,14 it should be reviewed by an expert 
hematopathologist.15 Since the first discovery in 1982 
by the Nobel prize-winning authors, B. Marshall and R. 
Warren16 Helicobacter pylori has become critical for 
treating and studying gastric disease like peptic ulcer, 
MALT lymphoma and gastric cancer.17 Hp 
identification mainly relies on histology (HE and 
modified Giemsa staining) and culture or invasive 
molecular tests.18 In the case of negativity, serology 
should be performed to identify truly negative gastric 
MALT lymphomas,19 in fact, Hp mucosal colonisation 
is not uniform, but in patches;20 therefore, the infection 
can go undiagnosed if biopsy involves a non-colonised 
area. In addition, it is believed that extensive mucosal 
lesion secondary to lymphoma may reduce the density 
of the infection to even undetectable levels.21,22 
 
Role of H. Pylori in MALT Lymphoma. Helicobacter 
species are the indigenous biota of mammalian 
stomachs, and H. pylori is the human-specific 
inhabitant,23 there is evidence that H. pylori has been 
present in humans at least since ancestors of 
Amerindians migrated from Asia more than 11,000 
years ago.24 In this long time span, Hp has adapted to 
human gastric environment establishing an interaction 
that can be interpreted as both commensalism and 
long-term parasitism.25 Extensive allelic diversity and 
genetic variability are hallmarks of this microaerophilic 
gram-negative bacterium,26 resulting from the 
combination of a high mutation rate27 and frequent 
exchange of genetic material during mixed strains 
infections.28 That extraordinary capacity of adaptation 
to human host (resembling a quasispecies) is the key to 
the success for this microorganism to infect more than 
one-half of the human population. H. pylori has been 
established by International Agency for Research on 
Cancer (IARC) to be definitive bacterial carcinogen for 
humans29 and is estimated to be responsible for 5.5% of 
all human cancer cases, about 592.000 new gastric 
cancer.30 Spectrum of H. pylori infection is wide with 
most carriers remaining asymptomatic while patients 
with duodenal ulcer have antral predominant gastritis 
with little mucosal atrophy and hyperacidity; patients 
with gastric ulcer almost invariably have corpus 
predominant gastritis and hypoacidity with various 
degree of mucosal atrophy,31 the latter condition is 
associated with gastric cancer.32 Moreover, the case of 
gastric MALT lymphoma is a rarer condition, 
accounting for <5% of primary gastric neoplasms. The 
epidemiological data raise the question why some 
people develop gastric cancer (also MALT lymphoma), 
and others do not? For example, what is the possible 
answer to the ‘African enigma’ where ubiquitous H. 
pylori infections is not associated with gastric cancer 
but only gastritis?33 On the other hand, in the setting of 
a developed Country like the Nord-East of Italy, where 
there is a higher prevalence of HP infection there is a 
concomitant high incidence of gastric lymphoma.34 
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Given that some simulations indicate that Hp seems to 
have spread from East Africa around 58,000 years ago 
following human migrations,35 we could hypothesize 
that in Africa, where H. pylori have interacted for more 
time with its human host, it could have reached a better 
symbiotic state with a decreased virulence. 
 
Pathogenesis of Helicobacter Pylori-Induced Gastric 
MALT Lymphoma. There are several known 
mechanism that Helicobacter exploits to interact with 
the host mucosa. Actually, H. pylori strains can be 
broadly categorized into strains that express multiple 
factors that interact with host tissue (CagA, s1-VacA, 
BabA, OipA) and strains that lack these factors (36). In 
1989, CagA was firstly identified 37 and is now 
recognized as a marker for strains that confers 
increased risk for peptic ulcer disease38 and gastric 
cancer.39 The Cag Type IV secretion system (T4SS) is 
the primary virulence determinant and is responsible 
for injecting macromolecules, in particular, CagA, 
inside epithelial cells.40 CagA is then tyrosine-
phosphorylated by the host cell Src kinase; once 
phosphorylated, CagA interacts with SHP-2, a tyrosine 
phosphatase, which affects spreading, migration, and 
adhesion of epithelial cells.41 Moreover, CagA protein 
interacts with Grb2 and activates the Ras/MEK/ERK 
pathway, leading to the phenotypes of cell scattering 
and proliferation.42 In addition, tyrosine-
phosphorylated CagA binds and activates C-terminal 
Src kinase (Csk) via its SH2 domain, which in turn 
inactivates the Src family of protein-tyrosine kinases. 
Since this signalling may induce apoptosis, the Csk 
pathway may attenuate the other CagA interactions.43 
In conclusion, attenuation of CagA activity by Csk may 
enable CagA-positive HP to infect the human stomach 
persistently for decades while avoiding excessive 
CagA toxicity to the host.43 There is also evidence that 
CagA can be directly injected by T4SS inside B-
lymphocytes. The delivered CagA induces the 
activation and stimulation of B cells (mediated by 
intracellular SHP-2 and phosphorylation of ERK and 
P38 MAPK), and could initiate the first step of 
transformation, also upregulating anti-apoptotic 
proteins BCl-2 and BCl-XL.44 Moreover, Kuo and 
colleagues have demonstrated the presence of the 
bacterial protein CagA inside malignant B cells of 
MALT lymphoma and that those patients tend to 
respond faster to HP eradication.45 
The vacuolating cytotoxin VacA, a high–molecular 
weight multimeric pore-forming protein is one of 
virulence factors produced by Hp and is responsible for 
epithelial cells by both apoptosis and programmed cell 
necrosis.46 VacA forms a pore that permeabilizes the 
epithelial cell plasma membrane to urea,47 that is an 
essential substrate for the H. pylori’s urease to mitigate 
acid gastric environment. More importantly, VacA 
determines immune suppression by blocking 
phagosome maturation in macrophages,48 inhibiting 
antigen presentation in T cells,49 blocking T cell 
proliferation with down-regulation of Th1 effects 
through interaction with calcineurin to block 
intracellular signalling.50 
Chronic H. pylori infection can trigger 
inflammation and immunological responses that 
stimulate lymphoid infiltration displaying features of 
classic MALT architecture.51 It is suggested that H. 
pylori infection results in T-cell-dependent responses 
through the classic germinal centre reaction, with 
generation of reactive B and T cells; the H. pylori-
specific T cells then migrate to the marginal 
zone/tumour area and provide non-cognate help to 
auto-reactive neoplastic B cells, which may involve 
stimulation of CD40 and other surface receptors by 
soluble ligands and cytokines.52,53 
Host polymorphisms are also a crucial determinant 
of the interaction with H. pylori and could elucidate 
why only rarely MALT lymphoma develops. 
Determinants of host immune response variability have 
been extensively reviewed by Datta De36 and mainly 
consist in variation in an inflammatory gene like IL-1 
(RN 2/2 genotype), glutathione S-transferase T1 null 
phenotype54 and a negative association with HLA-
B35.55 
An important proof of concept of the association of 
Hp with Gastric MALT were the first report by 
Wotherspoon of MALT regression after successful 
eradication of Hp.56 Those data have been corroborated 
by other studies,8,10 thus fulfilling Hill’s criteria of 
causality. 
 
Gastric MALT Beyond Helicobacter Pylori. After a 
clonal expansion of B-cell H. pylori-driven has 
established in gastric mucosa, other mutational events 
can explain the gain of independence from the 
infection itself. Three chromosomal translocations are 
the most frequently detected t(11;18)(q21;q21)/API2-
MALT1, t(1;14)(p22;q32)/BCL10-IGH, and 
t(14;18)(q32;q21)/IGH-MALT1, all converging to 
activation of nuclear factor kappa-B (NF-κB).53 
Translocation t(11;18)(q21;q21), occurring in 
approximately 30% of cases, fuses the N-terminus of 
the API2 gene to the C-terminus of the MALT1 gene 
and generates a functional API2-MALT1 fusion 
product,57,58 the other two translocations involve 
translocation to immunoglobulin gene loci, and 
consequently increased expression, of  BCL10 and 
MALT1 genes.12 Gastric MALT lymphomas carrying 
the t(11;18) are more aggressive with spread to local 
lymph nodes 59 and, most importantly, rarely respond 
to HP eradication.60,61 Therefore, its detection can 
influence the clinical management and is easily feasible 
with a commercial MALT1 dual-colour break-apart 
probe and an API2-MALT1 dual-colour dual-fusion 
probe for FISH, or by rt-PCR of the API2-MALT1 
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fusion mRNA transcripts.62 Not translocated cases 
frequently carry trisomies of chromosomes 3, 12 and 
18.63 
Gastric MALT lymphoma H. Pylori Negative. 
Another interesting setting is represented by gastric 
MALT lymphoma, H. pylori negative that responded to 
antibiotic treatment in 15.5% of cases, despite H. pylori 
triple negativity test.64,65 Those data have been 
interpreted by authors in light of a limited accuracy of 
H. pylori detection (false negative) or the possible 
presence of other unidentified bacteria implicated in 
MALT pathogenesis.65 Nowadays, given the limited 
toxicity, low costs and risk of low-grade lymphoma 
progression, antibiotic therapy is also recommended  in 
H. pylori- cases.66 
 
Antibiotic Treatment. As previously discussed, 
targeting H. pylori seems a logical first line approach 
for gastric MALT lymphoma. Several effective 
schemes are available for the treatment of H pylori 
infection.67-69 The antibiotic choice should be based 
mainly on the epidemiology of Hp resistance to 
clarithromycin. Therefore, in countries with a 
prevalence >15% (That is the case of Europe, with the 
exception of Northern States)70 antimicrobial 
susceptibility testing could be useful.18 The most 
commonly used regimen is triple therapy: a proton 
pump inhibitor (omeprazole)71 in association with 
amoxicillin and clarithromycin.72 Metronidazole can be 
substituted to amoxicillin in penicillin-allergic 
individuals. An alternative is represented by the 
Sequential treatment, which includes a 5-day period 
with PPI+amoxicillin, followed by a 5-day period with 
PPI-clarithromycin-metronidazole.73 For failure of the 
first line therapy or for clarithromycin-resistant isolated 
strains, it is available a bismuth-based quadruple 
therapy with omeprazole, bismuth salts, metronidazole 
and tetracycline (OBMT),74 an RCT using a 
combination of PPI and a single three-in-one capsule 
tablet showed improved eradication in comparison with 
standard triple therapy.75 Finally, in case of failure of 
the second-line treatment (bismuth-containing 
quadruple regimen), it is recommended to use the 
PPI-levofloxacin-amoxicillin regimen,76,77 always 
considering the rise in epidemiologic H. pylori 
resistance to levofloxacin.68 
MALT lymphoma response to H. pylori eradication 
is about 80%.65 However the length of time necessary 
to obtain a remission can span from few months to 
more than 12 months.  
 
Anti-Lymphoma Directed Treatment. In cases not 
responding to antibiotic treatment, a control of 
localised disease can be achieved with radiation 
therapy alone with moderate-dose involved-field 
radiotherapy (24–30 Gy) to the stomach and perigastric 
nodes.13,78 
Patients with the symptomatic systemic disease 
should be considered for systemic treatment that 
encompass the association of rituximab + 
chemotherapy. Rituximab in combination with 
chlorambucil has been proven in a randomised study 
by International Extranodal Lymphoma Study Group 
(IELSG)-19 where an excellent event-free-survival was 
achieved, superior to chlorambucil alone, although  no 
overall survival benefit has been shown. Aggressive 
anthracycline-containing regimens (CHOP-like) are not 
usually necessary and should be reserved for cases with 
transformation to high grade.13 
 
Marginal Zone Lymphoma and HCV. 
A heterogeneous group of lymphoproliferative 
disorders have been long suspected to be associated 
with HCV infection. HCV-related Mixed 
cryoglobulinemia (MC) is considered as a low-grade 
B-cell lymphoproliferative disorder,  characterized 
clinically by arthritis, cutaneous vasculitis (palpable 
purpura), and, occasionally associated with 
glomerulonephritis and by the presence of circulating 
cryoprecipitable immune complexes of more than one 
immunoglobulin class. MC is defined by laboratory 
findings: the presence of serum Ig that precipitate at 
low temperatures (< 37°C) and can solve by warming 
serum, that are produced by the lymphoproliferation of 
B-cells clones secreting pathogenic IgM with 
rheumatoid factor activity. MC can evolve into an overt 
B-cell NHL in approximately 8–10% of cases after a 
long period.79 
MZLs, in particular splenic (SMZL) and nodal 
MZL (NMZL), and other extranodal-MZL are the 
iNHL subtypes most frequently described as being 
HCV-related (80-82). SMZL is an indolent and rare 
entity, separately recognised by WHO,1,83 usually 
presenting with symptomatic splenomegaly, 
cytopenias, autoimmune phenomena, and serum 
monoclonal paraprotein; in some patients a leukemic 
phase characterized by circulating lymphocytes with 
villous projections defines the so-called Splenic 
lymphoma with villous lymphocytes (SLVL).84 SMZL, 
albeit rare, in a population-based study, has been 
reported with an incidence between 2001 and 2008 of 
0.13 per 100,000 person-years, accounting for 0.6% of 
all NHL cases85 and is the most common primary 
splenic lymphoma.86 SMZL incidence is higher among 
older (median age is 65 years), white and male (male-
to-female ratio of 1.2:1) population, in the United 
States.85 
NMZL is a distinct clinical-pathological subtype of 
MZL characterized by exclusive primary lymph node 
localization in the absence of extranodal or splenic 
disease.1 NMZLs represent only 1.5% to 1.8% of all 
lymphoid neoplasms; the most frequent clinical 
presentation is a generalized or, less frequently, 
localized lymphadenopathy. 
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Recently, Paulli et al. have reported a new subset of 
patients with extranodal HCV-related MZL 
characterized by a primary ‘lipoma-like’ subcutaneous 
presentation and an indolent clinical course.87 
 
Role of HCV in iNHL. Hepatitis C virus (HCV) is an 
enveloped, RNA virus of the Flaviviridae family; it 
comprises six major genotypes, whose prevalence 
varies among different population and countries. HCV 
is not only hepatotropic, causing infection of 
hepatocytes associated with hepatitis, liver cirrhosis 
and hepatocellular carcinoma (HCC), but is also 
responsible for other extrahepatic manifestations, of 
whose the most frequent is lymphoproliferation.88 
 
Models of Pathogenesis in HCV-Induced 
Lymphoproliferation. The mechanisms underlying B-
cell lymphoproliferation possibly induced, directly or 
indirectly, by HCV chronic infection are yet not fully 
understood. However, few experimental data suggest 
some clues to explain this phenomenon and have been 
reviewed elsewhere.89,90 
The first observation derives from the HCV chronic 
antigenic stimulation leading to continuous stimulation 
and selection of reactive B-clones. HCV-associated 
NHLs derive from B cells activated during HCV 
infection, with some of these B cells being specific for 
the protein HCV-E2, which is the primary target of 
antibody responses against HCV.91 Moreover, the 
monoclonal IgM component of type II MC is often 
encoded by the same set of Variable region genes, 
VH1-69, and Vk3-A27 and similarly the same genes can 
be demonstrated to be involved in some cases of HCV-
related NHL.92,93 The burden of these data suggests that 
HCV-associated lymphomas are derived from clonally 
expanded B cells stimulated by HCV-E2 protein. 
HCV is a positive, single-strand RNA virus, lacking 
a DNA intermediate in its replicative cycle. Thus, 
insertional mutagenesis in infected B-cells seems not 
possible. Moreover, there is conflicting evidence about 
the demonstration in B-cells of the negative RNA viral 
strand, which would be consistent with active viral 
replication. In fact, in a Japanese study negative-strand 
HCV RNA was detected in B cells only in 4 of the 75 
(5%) patients94 while no replicative intermediates were 
detected in another study.95 In addition, B-cells could 
be not suitable for virus entry because claudin-1, a 
membrane co-receptor required for HCV infection is 
not present in peripheral blood cells.96 
Conversely, more robust data exist supporting a 
direct B-cell stimulation by the engagement of CD81 
on their surface by a combination of HCV-E2 and anti-
CD81 antibodies leading to polyclonal activation of 
naïve, CD27- B-cells.97 
 
Antiviral Therapy. Since 1990, several Epidemiologic 
studies suggested an association between hepatitis C 
virus (HCV) infection and B-cell NHL, although with 
geographical heterogeneity due to the different 
prevalence of HCV seropositivity.98-102 Nevertheless, 
many of these studies suffered from methodologic 
restrictions such as their retrospective nature, the 
consideration of prevalent instead of incident cases, 
missing or inappropriate controls. In 2003, the 
GIMEMA group published an Italian case-control 
study performed with adequate epidemiologic methods 
that demonstrated a clear association between HCV 
infection and various types of B-NHL.103 Recently a 
larger case-control study of InterLymph NHL Subtypes 
Project hepatitis confirmed the increased risk of MZL 
in C virus seropositive patients (EMZL OR = 5.29, 
95% CI = 2.48 to 11.28).104 In 2002, Hermine et al. 
reported the first series of nine patients with SLVL in 
which a complete regression of lymphoma was 
obtained with antiviral treatment (AT) consisting of 
interferon (IFN) +/- ribavirin.105 As a control, the 
authors reported 6 pts. with the same disease, but 
without HCV infection, not responding to the same 
treatment. This argument suggested for the first time 
that viral eradication and not the direct anti-
proliferative effect of IFN was responsible for HCV-
related NHL regression. Many single cases 
subsequently confirmed this observation, although, due 
to the rarity of HCV-related NHL, very few 
prospective studies have been published. In 20 patients, 
Vallisa et al. demonstrated a complete response to 
antiviral treatment of different subtypes in 70% of 
indolent i-NHL.106 Recently a multicenter study of 
Fondazione Italiana Linfomi (FIL) recorded more than 
700 patients with i-NHL and HCV seropositivity, 
demonstrating that AT used in the first line in 100 pts 
produced 44 CR and 33 PR.107 A French prospective 
study of 116 HCV-positive patients with B-NHL 
revealed that within the MZL subgroup (n=45 pts.), 
84% (n=38) received AT and 61% (n=23) achieved a 
Sustained Virological Response.108 Moreover, outcome 
analysis showed a favourable association between OS 
and AT in MZL patients (P = 0.04).108 From these 
experiences, AT is, to date, considered the first-line 
approach for the cases of HCV-related indolent 
lymphoma, not requiring immediate chemo-
immunotherapy. The recent  introduction of new, 
highly active, antiviral treatments could clarify whether 
a pure antiviral approach,109-111 free from the 
confounding role of interferon,112 is equally or even 
more efficacious against lymphoma. 
 
Ocular Adnexa MALT Lymphoma. 
Ocular adnexa MALT lymphoma (OAML), although 
uncommon, is the third most frequently involved site of 
MZL with an incidence rate of 1.4/1,000,000 person-
years, with a median age of 65 years,6 thus accounting 
for 50-78% of all ocular lymphomas in Western 
Countries.113 Moreover, Danish and American SEER 
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data from surveillance registries have reported an 
increase in the incidence of OAML.114,115 Clinical 
presentation of orbital fat lymphomas involvement 
(75% of OAML) includes exophthalmos (27% of 
cases), palpable mass (19%), eyelid ptosis (6%), 
diplopia (2%), eyelid nodule, orbital oedema, epiphora 
and a variable degree of impaired ocular motility, while 
the most common sign for conjunctival lymphomas 
(25% of OAML) is the characteristic ‘salmon red 
patch’.116 OAML is an indolent lymphoma with a 
favourable clinical outcome emphasized by a 10-year 
overall survival of 81%, with no deaths from 
lymphoma for the patients treated with radiotherapy 117 
and 94% for the patients managed with ‘watch and 
wait’.118 Microscopically neoplastic cells are 
monocytoid, centrocytic-like or lymphoplasmocitoid 
and their immunophenotype is similar to that of other 
MALT lymphomas: CD20+, CD79a+, usually IgM+ 
with light-chain restriction, PAX5+, bcl-2+, TCL1+, 
CD11c+/-, CD43+/-,CD21+/-, CD35+/-, and IgD2, 
CD32, CD52, CD102, CD23-, cyclin D1-, bcl-6-, 
MUM1-.119 Frequent chromosomal alteration 
encompasses trisomy 3 in 62% of cases and trisomy 18 
in 47% of cases.120 In addition, the most common 
translocations in ocular adnexal MALT lymphomas are 
the t(11;18)(q21;q21)/API2-MALT1 and the t(14;18) 
(q32;q21)/IGH-MALT1.121 The immunoglobulin 
heavy-chain gene rearrangement is clonal in 55% of 
cases122 and shows somatic hypermutation in two-
thirds of these,123 with a majority of selected genes 
commonly implicated in the assembly of 
autoantibodies, hence supporting the view that OAML 
represents a clonal expansion of post-germinal-centre 
memory B-cells, where selection may have occurred 
driven by antigen stimulation.123 Moreover, in OAML a 
possible infectious association has been long proposed,  
Chlamidophila spp. and, to a lesser extent, H. pylori 
and HCV124 have been proposed as causative agents. 
Although the association with Hp is controversial,125 a 
more robust evidence is available for the role of C. 
psittaci.119,126 
 
Role of C. Psittaci in Ocular Adnexa MALT 
Lymphoma. Chlamydophila psittaci (CP) is an 
obligate intracellular bacterium responsible for 
psittacosis/ornithosis in birds and in humans after 
zoonotic infection through inhalation of aerosolized 
bacteria when exposed to infected birds or handling 
contaminated feathers, faecal material or carcasses.127 
CP infection is commonly asymptomatic with repeated 
infection cycles in humans but mainly involves the 
respiratory tract. CP has been reported as a potential 
trigger for OAML, and Ferreri et colleagues firstly 
showed the efficacy of antibiotic treatment.126 In this 
work CP DNA was found in lymphoma samples from 
32 of the 40 (80%) case-patients analysed, thus 
revealing a strong association between OAML and CP 
infection, also in light of the low seroprevalence in 
general population studies varying between 0 and 49% 
(median: 5–10%).128 Moreover, Ponzoni et al. reported 
the presence of CP in 74% OAML specimens by 
different techniques such as immunohistochemistry, 
immunofluorescence and laser-capture 
microdissection-assisted PCR inside infiltrating 
monocytes/macrophages.129 Nevertheless, significant 
variability in CP association with OAML has been 
reported in different geographical areas, ranging from 
47% in Germany to 35% in the East Coast of the USA, 
29% in the Netherlands, 13% in Italy, 12%  in UK and 
11% in Southern China,130 while no evidence of CP 
infection was found in cases from the South Florida 131 
and Japan.132 To sum up, the overall prevalence of CP 
infection in 423 cases of OAML reported in 14 
different papers is 19%.128 In conclusion, the possible 
role of methodological pitfalls and other interpretation 
bias or confounding factors should be carefully 
considered when interpreting the bacteria–lymphoma 
association, also focussing on the potential role for C. 
psittaci infection in lymphomagenesis.128 
 
Treatment. OAML is a rare indolent lymphoma, for 
its treatment no consensus is available because no 
prospective clinical trials have been conducted to 
define the optimal treatment approach for these 
patients.133 However, patients managed by a watch & 
wait for approach have a 10-years OS of 94%.118 
Moreover, limited toxicity and costs associated with 
antibiotic treatment should suggest the opportunity to 
target the possibly correlated infection by C. psittaci, in 
analogy with gastric MALT lymphoma and Hp 
eradication. A single antibiotic course of oral 
doxycycline at a dose of 100 mg, given twice a day, for 
3 weeks is the most popular regimen. In the first 
prospective trial of doxycycline, 20 of the 27 patients 
were progression free at 2 years; interestingly also 6 
CP DNA–negative patients of the 16 treated 
experienced lymphoma regression.134 A subsequent 
international prospective phase II trial was performed 
by IELSG: the prevalence of Cp positivity in OAML 
was 89%; in these naïve patients, after CP eradication, 
lymphoma regressed with an ORR of 65%, with 6 
complete and 16 partial responses.135 A larger Korean 
prospective trial, enrolling 90 patients, showed an ORR 
of 27%.136 Actually, a new prospective study (IELSG 
39) is enrolling patients 
(http://www.ielsg.org/trialsonfr.html). On the contrary, 
another retrospective study did not show any 
response,137 even if the short median follow-up of 9 
months could have hampered the proper assessment of 
response. Altogether, in 9 studies identified in the 
literature by Kiesewetter and Raderer, 131 patients 
were treated with doxycycline resulting in an ORR of 
45%, with CR achieved in 23 patients (18%) and PR 
achieved by 36 pts. (27%) (138). An interesting Italian 
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work by Govi et al. showed the efficacy of 
administration of 500 mg clarithromycin, twice a day, 
for 6-months, in relapsed/refractory EMZL after 
treatment with doxycycline.139 Over the anti-bacterial 
effect on unidentified pathogens, clarithromycin could 
exert a direct anti-proliferating effect on OAML. 
Patients who fail to respond to doxycycline therapy can 
be successfully salvaged with chemotherapy and/or 
radiotherapy. 
Anti-Lymphoma Directed Treatment. Standard 
treatment is based on surgical resection of the single 
lesion. Radiotherapy is known as a treatment modality 
with a high local control rate for primary OAML.140,141 
However, orbital irradiation can induce complications 
such as cataracts, keratitis, dry eye syndrome, and 
retinopathy.142 Even if no universally accepted 
radiation schedule is available, National Cancer Center 
Network guidelines recommend radiotherapy of 20 to 
30 Gy for initial treatment of early-stage non-gastric 
MZL of all sites and reirradiation for locally recurrent 
disease.  
Only limited data on chemotherapy for patients with 
OAML suggest different association and schedule. The 
oral agent chlorambucil is the most frequently used 
chemotherapy agent and has an extremely favourable 
toxicity. Complete responses are observed in 67% to 
100% of patients; however, long-term outcome data 
suggest that local recurrence occurs in up to 29% of 
patients.143-146 Only a few cases of OAML have been 
treated with rituximab as single-agent,  demonstrating 
high activity in both newly diagnosed and relapsed 
disease, although early recurrence is common.147-150 
Also, the association of rituximab and chlorambucil 
has been tested with encouraging results.151 CNS 
prophylaxis is not recommended since OAML rarely 
recurs to CNS.152 
 
Role of Borrelia Burgdorferi in Primary 
Cutaneous B-cell Lymphomas. 
MZL of the skin has an incidence rate of 1.1/1,000,000 
person-years 6 and is predominant among males across 
all ages. B. burgdorferi (Bb) infection has been 
associated with skin MZL in some cases in Europe, but 
not in the U.S., Asia and some parts of Europe, thereby 
challenging the aetiological role of this agent.153,154 In 
particular, in Bb endemic areas such as the Scottish 
Highlands155 or Austria,156 cutaneous MZL patients 
have demonstrated Borrelia infection in up to 40% 
cases, while no association was detected in two Italian 
case series.157,158 However, in a nonendemic region like 
France, Bb DNA was found in 19% of 16 cases with 
primary cutaneous MALT lymphoma.159 
Bb infection might be associated with chronic 
antigen-driven lymphomagenesis in the skin, which is 
the port of entry of this gram-negative spirochete, 
through a bite from Ixodid tick and is also the 
infectious agent of Lyme borreliosis.5,160 Moreover, in 
late Lyme borreliosis, lymphocytes may infiltrate the 
dermis and produce the characteristic borrelia 
“lymphocytoma”, a cutaneous B-cell pseudolymphoma 
characterized by ‘top-heavy’, mixed-cell lymphoid 
infiltrate, usually accompanied by the formation of 
lymphoid follicles with germinal centres.161 Lyme 
disease and primary cutaneous lymphoma may 
represent a continuous spectrum of pathological states 
viewed as a multistep progression from lymphocytoma 
to “pseudolymphoma” eventually leading to primary 
cutaneous B-cell Lymphoma, where evidence of B-cell 
monoclonality may help distinguish between the 
different stages of the disease.5 
Discordant data exist about cutaneous MZL 
recession after antibiotic treatment of Bb infection 
(generally consisting of cephalosporins +/- 
tetracyclines) and are based on case reports.138 In 
conclusion, Bb and its association with cutaneous MZL 
are currently the object of investigation, even if an 
antibiotic treatment may be attempted given the 
indolent nature of the disease.162 
 
 
Concluding Remarks. 
Marginal zone lymphoma is a fascinating clinical 
setting in which it has been clearly shown in several 
trials (see Table 1) that several therapies targeting the 
putative oncogenic infectious agent can induce steady 
lymphoma regression. It represents the proof of 
concept that a chronic stimulus on the immune system 
induced by an infectious agent, under particular host 
predisposition, may lead to the selection of abnormal 
B-clones and a more selection may result in overt 
lymphoma development. For gastric and the ocular 
adnexa MALT lymphomas the compelling evidence, to 
date, provides a rationale to implement actively 
antibiotics regimens that can be an effective first-line 
treatment due to the peculiar indolent course of the 
disease and the high therapeutic index of these drugs. 
Indeed, international guidelines state that “Helicobacter 
pylori eradication therapy must be given to all gastric 
MALT lymphomas, independently of stage”. 
Conversely, in OAML and MZL of the skin antibiotic 
treatment remains investigational, given the 
questionable results of the former and the paucity of 
data for the latter clinical setting. 
With the recent availability of new direct-acting 
antiviral agents for HCV infection, that promise a rapid 
and sustained virological response, there is increasing 
interest in their employment to treat HCV-related 
SMZL and NMZL; however, further studies are needed 
to assess this strategy. In conclusion, we hope new 
evidence can improve our understanding of the 
pathogenesis of lymphoma mediated by antigen-
dependent infectious agents, thus enabling the 
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availability of other alternative and efficacious anti- lymphoma treatments. 
 
Table 1. Most relevant studies evaluating the efficacy of anti-infectious therapy for MZL regression. 
Reference Disease Year Patients 
Antibacterial/Antiviral 
therapy 
ORR 
Response 
 
Median 
follow-up 
(range) 
in months 
Wundish T163 Gastric MALT 2005 120 
First line: amoxicillin + 
omeprazole for 2 weeks 
Second line:metronidazole + 
omeprazole + clarithromycin for 
10 days 
90% 
CR 96 (80%) 
PR 13 (10%) 
SD 11 (9%) 
75 
(2-116) 
Kim JS164 Gastric MALT 2007 111 
First line: omeprazole + 
amoxicillin + clarithromycin 
Second line: omeprazole + 
bismuthate + metronidazole + 
tetracycline 
85% 
CR 84 out of 99 
cases (84.8%) 
SD 15 out of 99 
cases (15.2%) 
41 
(11-125) 
Raderer M165 
Gastric MALT 
H pylori 
Negative 
2015 
24 
(13) 
Clarithromycin in all patients,   +/- 
metronidazole+/- amoxicillin +PPI 
46% 
CR 5 (38%) 
PR 1 ( 7%) 
SD 4 (31%) 
PD 3 (23%) 
95 
(42-181) 
Arcaini L107 
SMZL 27% 
MALT 22% 
2014 134 
IFN (47) 
(IFN+RBV 36) 
peg-IFN  87 (IFN+RBV in 82) 
77% 
First line: 
CR 44 (44%) 
PR 33(33%) 
SD 14(14%) 
NA 
Michot JM108 
MZL 39% 
DLBCL 39% 
2015 45 
Peg-interferon α + ribavirin 
In 6 pts peg-IFN+RBN+protease 
inhibitor 
AT 
78% 
 
AT-R 
100% 
AT only 14pts 
CR 8 
PR 3 
AT+R 8 pts 
CR 3 
PR 5 
31 
(19-71) 
Han JJ136 OAML 2015 90 
Doxycycline (100 mg bid) for 3 
weeks 
27% 
CR 24(27%) 
SD 34(37%) 
PD 31(34%) 
40.5 
(8–85) 
Ferreri AJ135 OAML 2012 34 
Doxycycline 100 mg bid for 3 
weeks 
65% 
CR 6 (18%) 
PR 16 (47%) 
SD 11 (32%) 
PD 1 (3%) 
37 
(15-62) 
Govi S139 OAML 2010 11 
Clarithromycin 500 mg bid for 6 
months 
45% 
CR 2 (18%) 
PR 3 (27%) 
SD 3 (27%) 
PD 3 (27%) 
25 
(12-35) 
R: rituximab, PPI: proton-pump inhibitors 
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